Welcome to LookChem.com Sign In|Join Free

CAS

  • or

36915-02-3

Post Buying Request

36915-02-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

36915-02-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 36915-02-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,9,1 and 5 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 36915-02:
(7*3)+(6*6)+(5*9)+(4*1)+(3*5)+(2*0)+(1*2)=123
123 % 10 = 3
So 36915-02-3 is a valid CAS Registry Number.

36915-02-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name sodium,6,8-bis(sulfanyl)octanoate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:36915-02-3 SDS

36915-02-3Relevant articles and documents

An efficient, economical synthesis of the novel anti-tumor agent CPI-613

Gibson, Frank S.,Gupta, Deepak,Shorr, Robert,Rodriguez, Robert

, p. 855 - 857 (2011)

An efficient and practical synthesis of the novel anti-tumor compound 6,8-dithiobenzyl octanoic acid, CPI-613 (2), was developed and executed on a practical scale. CPI-613 can be made in a single vessel from (±)-lipoic acid (1) via reductive opening of the disulfide ring followed by benzylation of the sulfhydryls with benzyl bromide. CPI-613 was isolated by simple crystallization in high yield and purity. The process is scaleable and has been demonstrated at up to 100 kg.

CPI-613: Antimitochondrial metabolism agent Treatment of hematological malignancies and solid tumors

Moro

, p. 209 - 214 (2017/05/17)

Metabolic changes specifically associated with cancer may constitute an excellent opportunity for the identification of new biomarkers and targets for novel drugs. The coenzyme lipoate is a key player in the control of cell metabolic fluxes and occupies a central position in tumor biology. Previous observations suggested that systemically delivered lipoate analogues might selectively disrupt cancer mitochondrial metabolism, potentially resulting in cancer cell death. CPI-613, the first member of a large set of lipoate analogues, specifically inhibits mitochondrial metabolism in a wide range of tumor cell lines, but not in normal cells, by mechanisms involving pyruvate dehydrogenase and α-ketoglutarate dehydrogenase enzyme complexes. There are 14 ongoing or completed phase I and phase II clinical trials on CPI-613, alone or in combination, showing promising results for several hematological malignancies and solid tumors, particularly for the treatment of acute myeloid leukemia, myelodysplastic syndrome and pancreatic cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 36915-02-3